<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75695">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090244</url>
  </required_header>
  <id_info>
    <org_study_id>PTH spinal stenosis</org_study_id>
    <secondary_id>2011-002917-12</secondary_id>
    <nct_id>NCT02090244</nct_id>
  </id_info>
  <brief_title>Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?</brief_title>
  <official_title>Förbättrar PTH Postero-lateral fusionsläkning Vid Ryggkirurgi?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council of Southeast Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parathyroid (PTH) hormone has been shown to enhance fracture healing in animal studies.
      There are so far only three published papers concerning humans. Postero-lateral fusions have
      shown a healing rate of less than 50% after bone. The purpose of this study is to determine
      if PTH 1-34 (teriparatide) improves the healing rate and the clinical course after spinal
      stenosis surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients undergoing surgery due to spinal stenosis and intraoperatively treated with
      autologous bone graft, will be randomised to either 4 weeks of daily injections with
      teriparatide or control.

      Primary outcome: The rate of healing at 6 months on CT Scans. Secondary outcomes; Pain
      (VAS), function (Oswestry Disability Index), quality of life (EQ-5D) at 3 and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The rate of bone healing after spinal stenosis surgery</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks</description>
    <arm_group_label>Teriparatide</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lumbar spinal stenosis operated on with decompression and bone grafting. All ages are
             accepted, but women must be postmenopausal.

        Exclusion Criteria:

          -  •dementia or psychiatric disorder

               -  known malignancy &lt; 5 years prior to fracture

               -  calcium above reference value

               -  signs of liver disease

               -  creatinine over ref. value

               -  inflammatory joint disease

               -  alcohol or drug abuse

               -  oral corticosteroid medication

               -  long-term NSAID-treatment (=&gt; 3 months prior to fracture)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Ottesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ryggkliniken, US Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrik Bernestrå, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ortopedkliniken, Kalmar, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torsten Johansson, MD PhD</last_name>
    <phone>+46-10-1034262</phone>
    <email>torsten.johansson@lio.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ortopedkliniken</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrik Bernestrå, MD</last_name>
      <phone>+46-48081332</phone>
      <email>patrik.bernestra@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Patrik Bernestra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ryggkliniken, US Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Ottesen, MD</last_name>
      <email>jon.ottesen@lio.se</email>
    </contact>
    <investigator>
      <last_name>Jon Ottesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 16, 2014</lastchanged_date>
  <firstreceived_date>March 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Torsten Johansson</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>PTH</keyword>
  <keyword>Spinal stenosis</keyword>
  <keyword>Teriparatide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
